- Corporate Governance
- Board of Directors
- Audit Committee
- Remuneration Committee
- Key Internal Policies
Ph.D., Business Administration, University of Kentucky, USA
MBA, National Chiao Tung University, Taiwan
Bachelor, Electronic Engineering, National Chiao Tung University, Taiwan
Major Work Experience
Senior Vice President and Chief Information Officer, TSMC
Chairman, Rafael Microelectronics, Inc.
Chairman and CEO, Neo Solar Power Corp.
Independent Director, Powertech Technology Inc.
Independent Director, CHROMA ATE INC.
Current Position
Director, United Renewable Energy Co., Ltd.
Director, Rafael Microelectronics, Inc.
Vice Chairman & Chief Strategy Officer, V5Med Inc.
Major Work Experience
Director, Newsoft Technology Corporation
Founder & CEO, Ebsuccess Solutions Inc.
President, ChiefSoft Technology Inc.
Senior Manager, IBM-New Development Center
Member of Technical Staff and Team Leader, AT&T-Bell Labs
Current Position
Chairman & President, Long Win Investment Company Limited
Chairman and CEO, Neo Solar Power Corp.
Vice General Manager & Head of Plant, Kwanghua Amorphous Silicon Co., Ltd.
Battery Pack of Materials Research Institute, Institute of Industrial Technology/Leader of Film Team
Host of Power Subsystem, Space Program by the National Space Center
Was honored as the highest in the international solar cells field, PVSEC-23 Special Award, Academician of Asia Pacific Institute of Materials
Current Position
Chairman & CSO, United Renewable Energy Co., Ltd.
Chairman, Yong Liang Ltd.
Director, United Renewable Energy
Engineering Co. , Ltd
Major Work Experience
Department Manager of BTSD, TSMC
Department Manager of BOSD, TSMC
Current Position
Chairman & President, V5Med Inc.
Major Work Experience
Manager, HON HAI PRECISION INDUSTRY CO., LTD.
Deputy Manager, LIEN CHANG ELECTRONIC ENTERPRISE CO., LTD.
Deputy Manager, First Capital Management,
Deputy Manager, Waterland Securities, Investment Consulting Co., LTD
Current Position
Director, TAN DE TECH CO., LTD.
Director, 3S SILICON TECH, INC.
Direcotr, Jorjin Technologies Inc.
B.S. in Electrical Engineering, Tatung University
Current Position
Director, HERMES-EPITEK CORPORATION
President, Hermes Advanced Therapy Systems Corp.
Chairman & President, SWIROC CORP.
Major Work Experience
Vice President of Citi Bank
General Manager of Salomon Smith Barney Inc. Taipei Branch, Citi Group
Chairman of Lehman Brothers Securities Taiwan Ltd.
Managing Director of Nomura International (Hong Kong) Limited, Taipei Branch
Current Position
Chairman, MILLERFUL ASSET MANAGEMENT CO., LTD.
B.S. in Electrical and Control Engineering, National Chiao Tung University
Major Work Experience
Co-founder of Acer
Chairman of Richtek Technology Corporation
Chairman of InveStar Capital, Inc
Current Position
Chairman, Investar corporation
Independent Director, TONG HSING ELECTRONIC INDUSTRIES, LTD.
Finance Vice President of Vanguard International Semiconductor Corporation
Current Position
Independent Director, EPISIL-PRECISION INC.
M.S. in Oceanography, National Taiwan University
LL.B., National Taiwan University
Dean, School of Law, National Yang Ming Chiao Tung University
Advisor, Intellectual Property Office of Singapore (IPOS) International
Current Position
Director of Institute of Financial Law and Crime Prevention
Independent Director of Taiwan Cooperative Bank
To ensure a fair, impartial, and transparent election of directors, the Company has established “Procedure s for Election of Directors” in accordance with the “Corporate Governance Best-Practice Principles for TWSE/TPEx Listed Companies.”
Unless otherwise stipulated by laws or the Article of Incorporation, the election of directors shall be conducted in accordance with these procedures.
The selection of directors shall take into account the overall composition of the Board of Directors. Board diversity is encouraged, and an appropriate diversity policy should be formulated based on the Company’s operations, business model, and development needs. This may include, but is not limited to, the following two dimensions:
1. Basic Criteria and Values: gender, age, nationality, and cultural background.
2. Professional Knowledge and Skills: expertise in areas such as law, accounting, industry, finance, marketing, or technology; as well as relevant skills and industry experience.
Members of the Board of Directors shall possess the necessary knowledge, skills, and competencies to perform their duties. The Board of Directors as a whole should have the following capabilities:
operational judgment, accounting and financial analysis, business management, crisis management, industry knowledge, international market perspective, leadership, and decision-making.
More than half of the seats on the Board of Directors shall not be held by individuals who are spouses or relatives within the second degree of kinship.
The composition of the Board of Directors shall be reviewed and adjusted based on the results of performance evaluations.
At least one independent director must possess accounting or financial expertise. An independent director of the Company shall not concurrently serve as an independent director in more than three other public companies.
The Company shall have between five and eleven directors, each serving a three-year term.
Starting from 2025 (Year 114 of the ROC calendar), the Company will fully adopt the candidate nomination system, with directors elected at the shareholders’ meeting from the list of nominated candidates.
Among the total number of directors, the Company shall appoint at least three independent directors, and such independent directors must account for no less than one-third of all board seats.
The qualifications, shareholding requirements, limits on concurrent positions, nomination and election process, and other relevant matters relating to independent directors shall comply with the regulations prescribed by the competent securities authority.
In accordance with Article 192-1 of the Company Act, the Company announced on July 16, 2025, the nomination period for director candidates (including independent directors), the number of seats to be filled, the submission location, and other required matters.
Shareholders holding 1% or more of the total issued shares may submit in writing a list of nominated director candidates to the Company.
The nominating shareholder must clearly state the name, educational background, and professional experience of the nominee, and attach supporting documents.
All nominations must be submitted by registered mail or delivered in person to the Company during the nomination period: July 18 to July 28, 2025.
During the nomination period, only nominations from the Board of Directors were received; no other shareholder nominations were submitted.
2. Approved the review of accounts receivable overdue for more than three months as of June 30, 2025.
3. Approved the adjustment of the position of Associate Vice President Andy Lin, Head of R&D.
4. Approved the appointment of the Company’s Chief Corporate Governance Officer and Finance Manager.
5. Approved the incentive bonus plan for managerial officers.
2. Approved the nomination of candidates for directors and independent directors.
3. Approved the release of non-compete restrictions for newly elected directors (including independent directors) and their representatives.
4. Approved the convening of the 2025 First Extraordinary Shareholders’ Meeting.
5. Approved the appointment and remuneration of the CPA for the year 2025.
2. Approved the proposal to conduct a cash capital increase and public offering of new shares prior to initial listing, with all original shareholders waiving their preemptive rights.
3. Approved the use of capital surplus to offset accumulated losses.
4. Approved the Company’s self-assessment of its ability to prepare IFRSs financial reports and the proposed improvement plan to enhance such capability.
5. Approved the acquisition of right-of-use assets from related parties.
6. Approved the credit line facilities with financial institutions.
7. Approved the amendment of certain articles of the Company’s Article of Incorporation.
8. Approved the revision of the Internal Control System and Internal Audit Implementation Rules.
9. Approved the amendment of key internal regulations.
10. Approved the change in the head of internal audit.
11. Approved the full re-election of the Company’s Board of Directors.
12. Approved the nomination of candidates for directors and independent directors.
13. Approved the release of non-compete restrictions for newly elected directors (including independent directors) and their representatives.
14. Approved the convening of the 2025 Annual General Meeting.
15. Approved the definition of the Company’s entry-level employee scope.
16. Approved the compensation management policy for directors, managerial officers, and functional committee members.
17. Approved the appointment of Associate Vice Presidents for R&D Division I, II, and III.
18. Approved the evaluation of compensation for directors (including independent directors), supervisors, managerial officers, and functional committee members.
2. Approved the restatement of the financial statements for the years 2022 and 2023.
3. Approved the 2024 Business Report and Financial Statements.
4. Approved the proposal for profit and loss appropriation for the year 2024.
5. Approved the ratification of the acquisition of right-of-use assets from related parties.
6. Approved the establishment of the “Procedures for Application for Halt and Resumption of TPEx Trading of Stock.”
7. Approved the establishment of the “Procedures for Reporting Changes in Insiders’ Positions.”
8. Approved the establishment of the “Audit Committee Charter” and “Rules Governing the Scope of Powers of Independent Directors.”
9. Approved the establishment of the “Ethical Corporate Management Best Practice Principles,” “Procedures for Ethical Management and Guidelines for Conduct,” and the “Code of Ethical Conduct.”
10. Approved the issuance of the Internal Control System Declaration for the year 2024.
11. Approved the establishment of the “Remuneration Committee Charter.”
12. Approved the establishment of the Compensation Committee and the appointment of the first-term committee members.
2. Approved the 2025 business plan and budget proposal.
3. Approved the appointment and remuneration of the CPA for the year 2024.
4. Approved the proposed capital increase in the Company’s subsidiary, V5med Inc. (“V5 Med”).
5. Approved the adjustment to the exercise schedule and ratio of the employee stock options issued in 2022.
6. Approved the proposed base date for capital increase related to the conversion of employee stock options into common shares.